Kristina M. Hellman

Array ( [id] => 16839471 [patent_doc_number] => 20210147483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => ANALOGUES OF HEPCIDIN MIMETICS WITH IMPROVED IN VIVO HALF LIFES [patent_app_type] => utility [patent_app_number] => 17/061336 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20670951 [patent_doc_number] => 12611446 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-28 [patent_title] => Cannabinoid product for improving musculoskeletal health [patent_app_type] => utility [patent_app_number] => 17/761664 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8375 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982602 [patent_doc_number] => 20220348638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => METHOD OF TARGETING NEURONAL APOE TO TREAT A NEUROCOGNITIVE DISORDER [patent_app_type] => utility [patent_app_number] => 17/763424 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091360 [patent_doc_number] => 20220409701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => PROCESS FOR PRODUCING A TABLET COMPRISING GLP-1 PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/638483 [patent_app_country] => US [patent_app_date] => 2020-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20744043 [patent_doc_number] => 12643934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-02 [patent_title] => Proinsulin peptides for Type 1 Diabetes [patent_app_type] => utility [patent_app_number] => 17/761151 [patent_app_country] => US [patent_app_date] => 2020-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 4083 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953647 [patent_doc_number] => 20240041974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => NANOEMULSION OPHTHALMIC COMPOSITION COMPRISING CYCLOSPORINE AND MENTHOL, AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 17/641793 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913818 [patent_doc_number] => 20210186910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/010601 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911397 [patent_doc_number] => 20220313792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => HEMOGLOBIN-BASED NANOPARTICLES FOR OXYGEN DELIVERY [patent_app_type] => utility [patent_app_number] => 17/638600 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881210 [patent_doc_number] => 20220296687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => NEUROTOXIN COMPOSITIONS FOR USE IN TREATING NEUROLOGIC AND PSYCHIATRIC DISORDERS [patent_app_type] => utility [patent_app_number] => 17/638673 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913236 [patent_doc_number] => 20220315631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => STAPLED BETA-CATENIN LIGANDS [patent_app_type] => utility [patent_app_number] => 17/639014 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897351 [patent_doc_number] => 20220307013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => GENE FRAGMENT OVEREXPRESSION SCREENING METHODOLOGIES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/638428 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49277 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -203 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512938 [patent_doc_number] => 20200392196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/003921 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806139 [patent_doc_number] => 20210128692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION [patent_app_type] => utility [patent_app_number] => 16/995466 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895418 [patent_doc_number] => 20220305080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => COMPOSITIONS AND METHODS UTILIZING A NOVEL HUMAN FOXO3 ISOFORM [patent_app_type] => utility [patent_app_number] => 17/635594 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468184 [patent_doc_number] => 20200369721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => CRYSTAL OF REDUCED GLUTATHIONE AND METHOD FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 16/988335 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830073 [patent_doc_number] => 20220267377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMPOSITIONS COMPRISING CHEMERIN ANALOGS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/631032 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631032 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805864 [patent_doc_number] => 20220257699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => PHARMACEUTICAL DEVELOPMENT [patent_app_type] => utility [patent_app_number] => 17/630645 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397337 [patent_doc_number] => 20200338195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS [patent_app_type] => utility [patent_app_number] => 16/930924 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16679 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16930924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16726543 [patent_doc_number] => 20210093690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => TOPICAL ANTIBIOTIC [patent_app_type] => utility [patent_app_number] => 16/946990 [patent_app_country] => US [patent_app_date] => 2020-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673120 [patent_doc_number] => 20210061883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => PROTEASE-ACTIVATED RECEPTOR-2 MODULATORS [patent_app_type] => utility [patent_app_number] => 16/926304 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16926304 [rel_patent_id] =>[rel_patent_doc_number] =>)